We established the UCSF Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF) in 2006 to accelerate the pace of research that improves the health of the public. The overall mission of CTSI has been to improve and transform clinical and translational research infrastructure and training at UCSF and our partner institutions. In the next funding period we aim to use the substantial knowledge, skills, and infrastructure that we have developed to further accelerate the pace of research at UCSF, to export our successes to other institutions, and to create initiatives aimed at improving the health of our own and other communities, through the following aims:
SPECIFIC AIM 1 : To enhance the highly successful activities of the UCSF CTSI, including the development of new initiatives in the areas of Training, Infrastructure/Services, and Advocacy/Culture Change: a) Training: to provide programs for students at all levels, across a spectrum of settings, and including all phases of the improvement of healthcare;b) Infrastructure/Services: to expand services and tools to clinical and translational investigators at UCSF, our partner institutions, and within the broader regional, national, and global communities;and, c) Advocacy/Culture Change: to nurture communication, encourage collaboration, foster innovation, and catalyze the successful conduct of clinical and translational research;to support a diverse faculty;to increase involvement of the community and the responsive of research to its needs;and change the academic culture to promote multidisciplinary, collaborative work.
SPECIFIC AIM 2 : To develop crosscutting initiatives using the knowledge, skills, and infrastructure developed by multiple CTSI programs in the first funding period to accelerate clinical and translational research and its impact on health, well beyond the institutions collaborating in the UCSF CTSI. New initiatives will: a) Bring together local public health and philanthropic groups to work with CTSI to improve the health of the San Francisco Bay Area community through a series of health improvement projects directed at high impact conditions;b) create a model system to accelerate the pace of clinical and translational research that includes streamlining regulation, developing participant recruitment services, providing research management, and bringing research services directly into community practices;and, c) improve the performance, transparency and accountability of research administration within and beyond CTSI by setting challenging goals and tracking performance metrics on public dashboards.
These aims will be achieved by orchestration of activities occurring within and between our 10 programs, supported by a proven governance model, and with strong ties to institutional and community leadership. Our ultimate goal is to bring better health to more people more quickly.

Public Health Relevance

CTSI aims to bring better health to more people more quickly by supporting training, infrastructure, advocacy, and culture change. CTSI achieves this goal not by conducting research but by making it easier for UCSF's superb investigators to conduct research. The current infrastructure and policy environment for clinical and translational research is inefficient, cumbersome and even obstructionist, so CTSI can only meet its goals if it also transforms the way research is done. Its goal is to build innovative infrastructure, tools and services, to transform the core university culture to one which promotes and rewards collaboration and accelerate the clinical application of basic science.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR000004-09
Application #
8737324
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Wilde, David B
Project Start
2006-09-30
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
9
Fiscal Year
2014
Total Cost
$19,370,123
Indirect Cost
$3,228,108
Name
University of California San Francisco
Department
Neurology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Durack, Juliana; Kimes, Nikole E; Lin, Din L et al. (2018) Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation. Nat Commun 9:707
Gradissimo, Ana; Lam, Jessica; Attonito, John D et al. (2018) Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Biomarkers Prev 27:1407-1415
Chorba, John S; Galvan, Adri M; Shokat, Kevan M (2018) A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9. J Vis Exp :
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Galárraga, Omar; Rana, Aadia; Rahman, Momotazur et al. (2018) The effect of unstable housing on HIV treatment biomarkers: An instrumental variables approach. Soc Sci Med 214:70-82
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Wehner, M R; Dalma, N; Landefeld, C et al. (2018) Natural history of lesions suspicious for basal cell carcinoma in older adults in Ikaria, Greece. Br J Dermatol 179:767-768
Liakoni, Evangelia; Gugelmann, Hallam; Dempsey, Delia A et al. (2018) Butanediol conversion to gamma-hydroxybutyrate markedly reduced by the alcohol dehydrogenase blocker fomepizole. Clin Pharmacol Ther :
Schafer, Anne L; Kazakia, Galateia J; Vittinghoff, Eric et al. (2018) Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly Impact Postmenopausal Women. J Bone Miner Res 33:975-986
Kimura, Takayuki; Kobiyama, Kouji; Winkels, Holger et al. (2018) Regulatory CD4+ T Cells Recognize Major Histocompatibility Complex Class II Molecule-Restricted Peptide Epitopes of Apolipoprotein B. Circulation 138:1130-1143

Showing the most recent 10 out of 662 publications